On June 7, Changchun High-tech Industry Co., Ltd. issued an announcement stating that the company and its subsidiary Baike Biotechnology Co., Ltd. intends to sign a "Limited Cooperation Agreement" with Guangzhou Si'anxin Biotechnology Co., Ltd. for obtaining the exclusive licensi

According to the announcement, Changchun Hi-Tech will pay a down payment of 35 million yuan to Si'anxin, Changchun Hi-Tech and Baike Bio will pay a total of 240 million yuan to Si'anxin in stages. After the product is launched, Changchun Hi-Tech will pay a sales milestone of 565 million yuan to Si'anxin Bio at the corresponding sales price and sales volume every year. The above payments will total RMB 840 million; at the same time, after the product is launched, Baike Bio will pay a certain proportion of sales commission to Si'anxin Bio at the corresponding sales price and sales volume every year until the patent authorization of the licensed patent expires.

announced that the novel coronavirus vaccine (PIV-5) involved in this license is derived from the parainfluenza virus (PIV-5) vector platform with independent intellectual property rights. It is administered through the nasal mucosa to induce humoral immunity, cellular immunity, and mucosal immunity. As the licensor of technology, Si'anxin is responsible for providing all research materials, data, biological materials related to licensing products and licensing technologies to Baike Bio, and assisting Baike Bio to complete preclinical research, phase I and phase II clinical work.

Changchun Hi-Tech emphasized in the announcement that if the products of this cooperation cannot achieve the expected results during the research and development process, it will bring more uncertain factors to the subsequent promotion of this cooperation and the implementation of the cooperation agreement by all parties. Investors are advised to pay attention to the investment risks of .

Changchun Hi-Tech is promoting two new crown vaccines under development

In addition to the latest disclosed novel coronavirus vaccine (PIV-5), Changchun Hi-Tech is also involved in the freeze-dried nasal spray recombinant new crown vaccine (influenza virus vector).

Changchun Hi-Tech was established in 1993 and was listed on Shenzhen Stock Exchange in 1996. It owns four major subsidiaries: Jinsai Pharmaceutical , Baike Biological, Huakang Pharmaceutical and Hi-Tech Real Estate. In May last year, Changchun Hi-Tech announced that it plans to split the of Baike Biological Science and Technology Innovation Board.

Freeze-dried nasal spray recombinant COVID-19 vaccine (influenza virus vector) is promoted by Baike Biologics. According to the prospectus (draft for filing) disclosed in 2020, this new crown vaccine under development is in the preclinical research stage in cooperation with Hong Kong University and Xiamen University . At the third quarter online performance briefing in October last year, Changchun Hi-Tech revealed that the research and development of the new crown vaccine has been arranged and has been smoothly promoted.

The latest progress in the listing of Baike Biotech is the disclosure of the prospectus on June 4, and plans to issue 41.28407 million shares, accounting for about 10% of the share capital after issuance. The preliminary inquiry date is June 9. Pengpai News reporter noticed that the latest prospectus also mentioned the freeze-dried nasal spray recombinant COVID-19 vaccine (influenza virus vector), but did not mention the latest progress.

Baike Bio's prospectus mentioned the development of the new crown vaccine

According to the prospectus, Baike Bio was established in March 2004. The main products on the market include chickenpox vaccine, human rabies vaccine, nasal spray influenza vaccine. In addition, 16 products are under development, of which 4 are in the clinical trial stage.

Changchun Hi-Tech has added capital to Si'anxin Bio-Tech

The other party authorized by the new crown vaccine (PIV-5) has a certain relationship with Changchun Hi-Tech.

According to the -day eye check data, Si'anxin Bio was established in 2019 with a registered capital of more than 11 million yuan. Its business scope includes medical research and experimental development (except human stem cells, gene diagnosis and treatment technology); drug research and development (except human stem cells, gene diagnosis and treatment technology); biotechnology development services (except my country's rare and unique rare and excellent varieties, except my country's rare and unique rare and excellent varieties, except my country's rare and unique rare and excellent varieties, except my country's wild animals and plant resources development) and so on.

It is worth noting that according to Tianyancha equity penetration, Changchun Hi-Tech is one of the shareholders of Si'anxin Bio.

According to an announcement by Changchun Hi-Tech on March 26 last year, on March 23, 2020, the company and Si'anxin Bio jointly signed the "Capital Increase Agreement" and the "Shareholder Agreement". The company plans to increase capital to Guangzhou Si'anxin in two phases in the form of capital increase and share expansion. The total proportion of equity of Guangzhou Si'anxin obtained by the two capital increase is 16.25%.

According to the announcement at the time, Changchun Hi-Tech said that the founder and legal representative of Si'anxin Biotechnology, He Biao, signed and took effect a series of technical license agreements through the American CyanVac, LLC and Si'anxin Biotechnology controlled by him. According to the licensing agreement, Si'anxin Bio has an exclusive license to include the Chinese rights of the respiratory syncytial virus (RSV) vaccine and a global rights to the other three vaccine products.

Changchun Hi-Tech believes that the above vaccines have relatively high development value and market potential, which can enable the company to expand its product types, meet the company's needs for further development, and accelerate the company's internationalization process.

As of the close of June 7, Changchun Hi-Tech reported 424.5 yuan per share, down 1.61%, with a market value of 171.8 billion yuan.

Editor in charge: Wang Jie